| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/15/2022 | 579.69% | HC Wainwright & Co. | → $2.4 | Initiates Coverage On | → Buy |
| 12/22/2021 | 1599.24% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 12/21/2021 | 1599.24% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 09/02/2020 | -29.2% | Aegis Capital | $2.15 → $0.25 | Downgrades | Buy → Hold |
| 09/01/2020 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 09/01/2020 | 41.6% | B. Riley Securities | $2 → $0.5 | Downgrades | Buy → Neutral |
| 07/06/2020 | 466.41% | B. Riley Securities | → $2 | Upgrades | Neutral → Buy |
| 05/06/2020 | 508.89% | Aegis Capital | $3 → $2.15 | Maintains | Buy |
| 02/18/2020 | 749.62% | HC Wainwright & Co. | $6 → $3 | Maintains | Buy |
| 01/13/2020 | 466.41% | B. Riley Securities | → $2 | Downgrades | Buy → Neutral |
| 11/18/2019 | 2165.65% | B. Riley Securities | → $8 | Reinstates | → Buy |
| 08/29/2019 | 2094.85% | B. Riley Securities | → $7.75 | Initiates Coverage On | → Buy |
| 07/18/2019 | 1882.44% | Oppenheimer | → $7 | Initiates Coverage On | → Outperform |
| 06/26/2019 | 1599.24% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 01/05/2018 | 1882.44% | Benchmark | → $7 | Initiates Coverage On | → Speculative Buy |
What is the target price for Acasti Pharma (ACST)?
The latest price target for Acasti Pharma (NASDAQ: ACST) was reported by HC Wainwright & Co. on December 15, 2022. The analyst firm set a price target for $2.40 expecting ACST to rise to within 12 months (a possible 579.69% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acasti Pharma (ACST)?
The latest analyst rating for Acasti Pharma (NASDAQ: ACST) was provided by HC Wainwright & Co., and Acasti Pharma initiated their buy rating.
When is the next analyst rating going to be posted or updated for Acasti Pharma (ACST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acasti Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acasti Pharma was filed on December 15, 2022 so you should expect the next rating to be made available sometime around December 15, 2023.
Is the Analyst Rating Acasti Pharma (ACST) correct?
While ratings are subjective and will change, the latest Acasti Pharma (ACST) rating was a initiated with a price target of $0.00 to $2.40. The current price Acasti Pharma (ACST) is trading at is $0.35, which is within the analyst's predicted range.
